Voyager Therapeutics Share Price (NASDAQ: VYGR)

$3.37

▲

-0.03

(-0.88%)

Last updated on August 30, 2025 at 1:29 am IST

$₹

Check the interactive Voyager Therapeutics Stock chart to analyse performance

Voyager Therapeutics stock performance

as on August 30, 2025 at 1:29 am IST

Today's Low:$3.33
Today's High:$3.42
$3.37
1.19%
Downside
Day's Volatility :2.63%
Upside
1.46%
52 Weeks Low:$2.65
52 Weeks High:$8.28
$3.37
21.51%
Downside
52 Weeks Volatility :68.04%
Upside
59.27%

Voyager Therapeutics Stock Returns

Period	Voyager Therapeutics, Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	2.28%	3.6%	0.0%
6 Months	-13.94%	-7.7%	0.0%
1 Year	-46.16%	-12.6%	0.0%
3 Years	-47.67%	9.5%	-4.7%

Voyager Therapeutics, Inc. Key Stats

Check Voyager Therapeutics key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$3.4
Open	$3.42
Today's High	$3.42
Today's Low	$3.33
Market Capitalization	$188.6M
Today's Volume	$203.3K
52 Week High	$8.275
52 Week Low	$2.645
Revenue TTM	$42.6M
EBITDA	$-118.9M
Earnings Per Share (EPS)	$-1.86
Profit Margin	-253.49%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-37.26%

Stock Returns calculator for Voyager Therapeutics Stock including INR - Dollar returns

The Voyager Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Voyager Therapeutics investment value today

Current value as on today

₹56,656

Returns

₹43,344

(-43.34%)

Returns from Voyager Therapeutics Stock

₹48,628 (-48.63%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Voyager Therapeutics Stock

-63%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Search interest for Voyager Therapeutics Stock from India on INDmoney has decreased by -63% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Voyager Therapeutics, Inc.

Name
Holdings %
Name
Holdings %
BlackRock Inc
9.76%
Armistice Capital, LLC
8.66%
EcoR1 Capital, LLC
7.07%
Vanguard Group Inc
5.79%
Farallon Capital Management, L.L.C.
4.64%
Dimensional Fund Advisors, Inc.
2.56%

Analyst Recommendation on Voyager Therapeutics Stock

Rating

Trend

Buy

87%Buy

12%Hold

0%Sell

Based on 16 Wall street analysts offering stock ratings for Voyager Therapeutics(by analysts ranked 0 to 5 stars)

Voyager Therapeutics Share Price Target

What analysts predicted

Upside of 364.89%

Target:

$15.67

Current:

$3.37

Voyager Therapeutics share price target is $15.67, a slight Upside of 364.89% compared to current price of $3.37 as per analysts' prediction.

Voyager Therapeutics Stock Insights

Price Movement
In the last 1 year, VYGR stock has moved down by -48.7%
Decreasing Revenue
Revenue is down for the last 2 quarters, 6.47M → 5.2M (in $), with an average decrease of 19.7% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, -31.02M → -33.38M (in $), with an average decrease of 7.6% per quarter
VYGR vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 69.9% return, outperforming this stock by 118.6%
VYGR vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 112.6% return, outperforming this stock by 152.5%
Price to Sales
ForVYGR every $1 of sales, investors are willing to pay $4.6, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.5 for every $1 of sales.

Voyager Therapeutics, Inc. Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$104.4M	↑ 1270.14%
Net Income	$-40.8M	↓ 53.75%
Net Profit Margin	-39.11%	↑ 1119.68%

	FY20	Y/Y Change
Revenue	$171.1M	↑ 63.93%
Net Income	$36.7M	↓ 189.98%
Net Profit Margin	21.47%	↑ 60.58%

	FY21	Y/Y Change
Revenue	$37.4M	↓ 78.14%
Net Income	$-66.0M	↓ 279.72%
Net Profit Margin	-176.49%	↓ 197.96%

	FY22	Y/Y Change
Revenue	$40.9M	↑ 9.33%
Net Income	$-46.4M	↓ 29.72%
Net Profit Margin	-113.45%	↑ 63.04%

	FY23	Y/Y Change
Revenue	$250.0M	↑ 511.16%
Net Income	$132.3M	↓ 385.14%
Net Profit Margin	52.93%	↑ 166.38%

	FY24	Y/Y Change
Revenue	$80.0M	↓ 68.0%
Net Income	$-65.0M	↓ 149.12%
Net Profit Margin	-81.25%	↓ 134.18%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$19.5M	↓ 78.33%
Net Income	$-11.3M	↓ 120.09%
Net Profit Margin	-58.05%	↓ 120.67%

	Q2 FY24	Q/Q Change
Revenue	$29.6M	↑ 51.56%
Net Income	$-10.1M	↓ 10.49%
Net Profit Margin	-34.29%	↑ 23.76%

	Q3 FY24	Q/Q Change
Revenue	$24.6M	↓ 16.73%
Net Income	$-9.0M	↓ 10.82%
Net Profit Margin	-36.72%	↓ 2.43%

	Q4 FY24	Q/Q Change
Revenue	$6.3M	↓ 74.51%
Net Income	$-34.5M	↑ 281.32%
Net Profit Margin	-549.33%	↓ 512.61%

	Q1 FY25	Q/Q Change
Revenue	$6.5M	↑ 3.11%
Net Income	$-31.0M	↓ 10.05%
Net Profit Margin	-479.24%	↑ 70.09%

	Q2 FY25	Q/Q Change
Revenue	$5.2M	↓ 19.67%
Net Income	$-33.4M	↑ 7.61%
Net Profit Margin	-641.96%	↓ 162.72%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$104.4M	↑ 1270.14%

	FY20	Y/Y Change
Profit	$62.4M	↓ 40.25%

	FY21	Y/Y Change
Profit	$37.4M	↓ 40.02%

	FY22	Y/Y Change
Profit	$40.9M	↑ 9.33%

	FY23	Y/Y Change
Profit	$245.6M	↑ 500.31%

	FY24	Y/Y Change
Profit	$80.0M	↓ 67.42%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$18.3M	↓ 79.35%

	Q2 FY24	Q/Q Change
Profit	$-4.9M	↓ 126.6%

	Q3 FY24	Q/Q Change
Profit	$24.6M	↓ 605.31%

	Q4 FY24	Q/Q Change
Profit	$6.3M	↓ 74.51%

	Q1 FY25	Q/Q Change
Profit	$6.5M	↑ 3.11%

	Q2 FY25	Q/Q Change
Profit	$5.2M	↓ 19.67%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$48.7M	↓ 406.33%
Investing Cash Flow	$-90.5M	↓ 441.85%
Financing Cash Flow	$81.0M	↑ 1605.5%

	FY20	Y/Y Change
Operating Cash Flow	$-96.7M	↓ 298.73%
Investing Cash Flow	$113.0M	↓ 224.89%
Financing Cash Flow	$3.2M	↓ 96.09%

	FY21	Y/Y Change
Operating Cash Flow	$-53.5M	↓ 44.66%
Investing Cash Flow	$65.9M	↓ 41.67%
Financing Cash Flow	$612.0K	↓ 80.65%

	FY22	Y/Y Change
Operating Cash Flow	$-12.5M	↓ 76.63%
Investing Cash Flow	$-7.3M	↓ 111.14%
Financing Cash Flow	$1.1M	↑ 81.37%

	FY23	Y/Y Change
Operating Cash Flow	$77.9M	↓ 722.9%
Investing Cash Flow	$-141.6M	↑ 1830.0%
Financing Cash Flow	$33.6M	↑ 2931.08%

	FY24	Y/Y Change
Operating Cash Flow	$-15.3M	↓ 119.65%
Investing Cash Flow	$-94.9M	↓ 33.03%
Financing Cash Flow	$114.0M	↑ 238.88%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$58.8M	↓ 347.34%
Investing Cash Flow	$-96.1M	↓ 458.01%
Financing Cash Flow	$112.9M	↑ 24433.91%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-31.6M	↓ 153.74%
Investing Cash Flow	$-35.9M	↓ 62.58%
Financing Cash Flow	$571.0K	↓ 99.49%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-28.0M	↓ 11.44%
Investing Cash Flow	$64.4M	↓ 279.04%
Financing Cash Flow	$14.0K	↓ 97.55%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-14.5M	↓ 48.05%
Investing Cash Flow	$-27.2M	↓ 142.27%
Financing Cash Flow	$574.0K	↑ 4000.0%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-37.9M	↑ 160.82%
Investing Cash Flow	$41.2M	↓ 251.46%
Financing Cash Flow	$82.0K	↓ 85.71%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$-33.3M	↓ 12.23%
Investing Cash Flow	$1.9M	↓ 95.31%
Financing Cash Flow	$513.0K	↑ 525.61%

Voyager Therapeutics Technicals Summary

Sell

Neutral

Buy

Voyager Therapeutics is currently in a neutral trading position according to technical analysis indicators.

Voyager Therapeutics, Inc. Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Voyager Therapeutics, Inc.	5.49%	-13.94%	-46.16%	-47.67%	-70.87%
Regeneron Pharmaceuticals, Inc.	6.48%	-15.2%	-50.31%	-3.3%	-2.01%
Beone Medicines Ltd	1.77%	24.81%	62.78%	79.11%	29.69%
Vertex Pharmaceuticals Incorporated	-14.45%	-19.13%	-17.84%	34.68%	41.87%
Alnylam Pharmaceuticals, Inc.	13.79%	83.28%	75.87%	111.28%	242.25%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Voyager Therapeutics, Inc.	6.02	NA	0.0	-2.11	-0.37	-0.2	NA	4.4
Regeneron Pharmaceuticals, Inc.	14.6	14.6	1.2	39.42	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.73	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	27.86	27.86	0.58	18.06	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Voyager Therapeutics, Inc.	Buy	$188.6M	-70.87%	6.02	-253.49%
Regeneron Pharmaceuticals, Inc.	Buy	$61.4B	-2.01%	14.6	31.37%
Beone Medicines Ltd	NA	$36.5B	29.69%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$100.5B	41.87%	27.86	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$59.5B	242.25%	NA	-12.96%

About Voyager Therapeutics, Inc.

Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. The company's lead product candidate is VY7523, an anti-tau antibody program for the treatment of alzheimer's disease (AD). Its product pipeline includes VY1706, a tau silencing gene therapy in preclinical trial for the treatment of alzheimer's disease; SOD1 silencing gene therapy program for treating amyotrophic lateral sclerosis in preclinical trial; and vectorized anti-amyloid antibody early research program for the treatment of AD in preclinical trial. The company is also developing VY-FXN01 for treating friedreich's ataxia; and GBA1 gene replacement program to treat parkinson's disease. In addition, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Neurocrine Biosciences, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

Organization	Voyager Therapeutics
Employees	172
CEO	Dr. Alfred W. Sandrock Jr., M.D., Ph.D.
Industry	Health Technology

Key Management of Voyager Therapeutics, Inc.

Name	Title
Dr. Alfred W. Sandrock Jr., M.D., Ph.D.	President, CEO & Director
Dr. Nathan D. Jorgensen M.B.A., Ph.D.	CFO, Principal Financial Officer & Principal Accounting Officer
Mr. Toby Ferguson M.D., Ph.D.	Chief Medical Officer
Dr. Krystof Bankiewicz M.D., Ph.D.	Founder
Dr. Mark A. Kay M.D., Ph.D.	Founder
Ms. Robin Swartz	Chief Business Officer & COO
Mr. Todd Carter Ph.D.	Chief Scientific Officer
Ms. Trista Morrison	Chief Corporate Affairs Officer & Chief of Staff to the CEO

Important FAQs about investing in VYGR Stock from India :

What is Voyager Therapeutics share price today?

Voyager Therapeutics share price today is $3.37 as on August 30, 2025 at 1:29 am IST at the close of the market. Voyager Therapeutics share today touched a day high of $3.42 and a low of $3.33.

What is the 52 week high and 52 week low for Voyager Therapeutics share?

Voyager Therapeutics share touched a 52 week high of $8.28 and a 52 week low of $2.65. Voyager Therapeutics stock price today i.e. August 30, 2025 at 1:29 am IST is closed at $3.37, lower by 59.27% versus the 52 week high.

How to invest in Voyager Therapeutics Stock (VYGR) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Voyager Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Voyager Therapeutics Shares that will get you 0.4451 shares as per Voyager Therapeutics share price of $3.37 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Voyager Therapeutics Stock (VYGR) from India?

Indian investors can start investing in Voyager Therapeutics (VYGR) shares with as little as ₹88.286 or $1 (as of August 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Voyager Therapeutics stock (as per the Rupee-Dollar exchange rate as on August 31, 2025). Based on Voyager Therapeutics share’s latest price of $3.37 as on August 30, 2025 at 1:29 am IST, you will get 2.9674 shares of Voyager Therapeutics. Learn more about fractional shares .

What are the returns that Voyager Therapeutics has given to Indian investors in the last 5 years?

Voyager Therapeutics stock has given -70.87% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?